Multimarker Serum Tests Related to Ovarian Cancer Testing

This policy establishes that all multianalyte/multimarker serum tests related to ovarian cancer (e.g., Ova1, Overa/MIA2G, ROMA) are non-covered for any indication. The tests are not covered as screening tools or standalone diagnostics and should not be used without independent clinical and imaging evaluation; the FDA-cleared intended use (women >=18 with an adnexal mass pending planned surgery and not yet referred to an oncologist) is informational and does not imply coverage.

"All multianalyte/multimarker serum tests related to ovarian cancer (multimarker serum tests/MAAA), including Ova1, Overa (MIA2G), and ROMA, are not covered for any indication."

Sign up to see full coverage criteria, indications, and limitations.